Amyloidogenicity and Cytotoxicity of a Recombinant C‑Terminal His6‑Tagged Aβ1–42

• Published in: ACS chemical neuroscience Vol. 10; no. 3; pp. 1251 - 1262
• Main Authors: Jia, Longgang, Wang, Wenjuan, Sang, Jingcheng, Wei, Wei, Zhao, Wenping, Lu, Fuping, Liu, Fufeng
• Format: Journal Article
• Language: English; Japanese
• Published: American Chemical Society 20-03-2019
• Subjects: hexahistidine tag; aggregation; Alzheimer’s disease; molecular dynamics; amyloid β peptide; cytotoxicity
• ISSN: 1948-7193; 1948-7193
• DOI: 10.1021/acschemneuro.8b00333

Aggregation of amyloid β peptide (Aβ) is closely associated with the occurrence and development of Alzheimer’s disease (AD). Reproducible and detailed studies on the aggregation kinetics and structure of various aggregates have been conducted using recombinant Aβ peptides. While the His6-tag is commonly used in the purification of recombinant proteins due to its great simplicity and affinity, there is little information on the aggregation of His6-tagged Aβ and its corresponding cytotoxicity. Moreover, it is also unclear whether there is an effect of the His6-tag on the amyloidogenicity and cytotoxicity of recombinant Aβ1–42. Herein, a method to express and purify a mutant C-terminally His6-tagged Aβ1–42 (named as Aβ1–42-His6) from Escherichia coli was described. Aβ1–42-His6 aggregated into β-sheet-rich fibrils as shown by thioflavin T fluorescence, atomic force microscopy and circular dichroism spectroscopy. Moreover, the fibrillar recombinant Aβ1–42-His6 showed strong toxicity toward PC12 cells in vitro. Molecular dynamics simulations revealed that the His6-tag contributed little to the secondary structure and intermolecular interactions, including hydrophobic interactions, salt bridges, and hydrogen bonding of the fibrillar pentamer of Aβ1–42. This highlights the biological importance of modification on the molecular structure of Aβ. Thus, the easily purified high-quality Aβ1–42-His6 offers great advantages for screening aggregation inhibitors or in vitro confirmation of rationally designed drugs for the treatment of AD.